Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. has received an administrative regulatory measure from the Jilin Securities Regulatory Bureau, addressing issues related to the mixed use of properties with its controlling shareholder, lack of lease agreements, and rent payments, which the company is committed to rectify [1] Group 1: Regulatory Measures - The company acknowledges the regulatory measures and emphasizes its commitment to comply with relevant laws and regulations, aiming to enhance corporate governance [1] - The identified issues reflect weaknesses in the company's governance structure and independent management, prompting a comprehensive internal management system improvement [1] - The regulatory measures are characterized as routine oversight and are not expected to impact the company's normal production and operational activities [1] Group 2: Financial Performance and Growth - The company forecasts a net profit of approximately 1.242 billion yuan for 2025, indicating a turnaround from losses compared to the previous year [2] - The anticipated profit increase is primarily driven by the company's competitive advantage in insulin procurement, leading to rapid market share growth for insulin products [2] - The company has also seen significant growth in other products, such as liraglutide injection and empagliflozin tablets, contributing to a substantial rise in domestic sales revenue [2] Group 3: Strategic Focus - As a leading player in the domestic insulin market, the company plans to continue focusing on its core business, increasing R&D investment, and advancing international expansion [2] - The company aims to optimize its product structure and enhance core competitiveness while maintaining stable operational performance and improving corporate governance [2]

国内市场方面，公司依托本次胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市 场份额迅速提升;同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带 动国内销售收入较上期大幅攀升。 智通财经APP讯，通化东宝(600867.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润约为12.42亿元，与上年同期相比，将实现扭亏为盈。 ...

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 曾健辉） 每经AI快讯，通化东宝1月26日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 约为12.42亿元，与上年同期相比，将实现扭亏为盈。业绩变动主要原因是，主营业务影响。国内市场 方面，公司依托本次胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市场份额迅 速提升；同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带动国内销 售收入较上期大幅攀升。公司国际化战略成效显著，出口收入增长明显。非经营性损益的影响。公司转 让厦门特宝生物工程股份有限公司股权产生收益，导致净利润大幅增加。 ...